The GI Dynamics SAB was created to help the company advance the body of evidence supporting clinical use of EndoBarrier, ask and answer relevant questions about the treatment paradigm, and advance the state of patient care for type 2 diabetes and obesity. The group will serve as a critical resource to GI Dynamics during the investigational device exemption trial of EndoBarrier in the United States, and will support ongoing clinical studies and commercialization in the United Kingdom, Germany, the Middle East, and additional European countries.
“We look forward to working with professors Le Roux and Greve to help us improve clinical options for patients with type 2 diabetes and obesity with EndoBarrier,” said Scott Schorer, GI Dynamics president and CEO. “As an endocrinologist, professor Le Roux brings a deep understanding of the disease states we are treating. Professor Greve, who has been a primary investigator on two EndoBarrier trials, brings the perspective of an experienced bariatric/metabolic surgeon.”
Le Roux serves as the head of pathology at the University College Dublin in Ireland. He graduated from medical school in Pretoria, South Africa, where he completed his specialist training in metabolic medicine at St. Bartholomew’s Hospitals and Hammersmith Hospitals. He completed his Ph.D. at Imperial College London and was later promoted to Reader. He received a Clinician Scientist Award from the U.K. National Institute of Health Research and a Wellcome Trust Clinical Research Fellowship for his work on how the gut communicates with the brain.
“Type 2 diabetes remains one of the most challenging chronic diseases people struggle with. Novel and scalable treatments that can have a positive impact on people’s lives are urgently needed,” said Le Roux. “EndoBarrier has broken the mold of how we used to think about novel treatments for diabetes.”
Greve serves as medical director of the Dutch Obesity Clinics South and chair of the Metabolic and Bariatric Surgery Unit at the Zuyderland Medical Center in the Netherlands. Greve received his Ph.D. at the Academic Hospital in Maastricht, Netherlands, has served on numerous committees, supervised 15 doctoral theses, and authored more than 185 peer-reviewed papers and numerous book chapters on intensive care medicine, nutrition, and bariatric and metabolic surgery. He was principal investigator of two European EndoBarrier clinical trials and other single-center and multicenter studies.
“Obesity and its co-morbidities are an immense challenge for modern health care,” said Greve. “Bariatric or metabolic surgery is a proven tool to treat morbidly obese patients with type 2 diabetes. However, the majority of these patients may have a BMI that is too low or have serious contraindications that preclude them from being candidates for such an invasive surgical procedure. As a bariatric / metabolic surgeon, I believe EndoBarrier is a powerful addition to our treatment armamentarium.”
GI Dynamics Inc. is the developer of EndoBarrier, the first endoscopically delivered device approved for the treatment of type 2 diabetes and obesity. EndoBarrier is approved and commercially available in multiple countries outside the United States. EndoBarrier is not approved for sale in the United States and is limited by federal law to investigational use only in the United States. Founded in 2003, GI Dynamics is headquartered in Boston, Mass.